We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Costly Blood Clot Test Has Few Benefits

By LabMedica International staff writers
Posted on 17 Nov 2016
It has been proposed that hospital patients, who have already been diagnosed with venous thromboembolisms or VTEs, do not need a positive genetic test to justify taking medication and making other changes to prevent future ones.

The hereditary thrombophilias are a group of inherited conditions that predispose to thrombosis. More...
Heritable deficiencies of the endogenous anticoagulants protein C, protein S, and antithrombin have been recognized for some years, but their prevalence, even among patients with familial thrombosis, is low.

Scientists at the University of Michigan Medical School (Ann Arbor, MI, USA) have reviewed the ordering of inherited thromboembolism testing on inpatients. There are several tests for several traits, so patients often get them in combination, what's called a hypercoagulable workup. But if doctors are following guidelines grounded in evidence, the test result should rarely change a patient's care. Often, it appears, the test gets ordered to satisfy curiosity about why a patient had a VTE, to see if they are among the 7% of Americans with a genetic mutation that makes blood more prone to clot. So, except in very specific cases where such clots are highly likely, such as women with a family history of clots who are pregnant or getting hormone replacement therapy, there is little reason to do the test at all for inherited thrombophilia.

Ideally, genetic tests to find out whether someone carries a certain genetic trait should be used when there is clear information about the risks, benefits and costs of that test. However the team illustrated the situation by applying this information to a hypothetical case of a young patient with a VTE but no family history who suffers a pulmonary embolism, a dangerous health emergency where clots form in the lower extremities and travel to the lungs, potentially cutting off oxygen to the body unless treatment starts quickly.

The scientists note the conclusions about VTE prevention and treatment that have been reached by several medical bodies that recommend against giving clot-prevention medication to people with the genetic trait but no VTE history. Lauren Heidemann, MD, an assistant professor of medicine and first co-author, said, “Physicians and patients should resist the temptation to perform costly search for an underlying genetic cause of venous thrombosis.” The study was published on October 26, 2016, in the Journal of Hospital Medicine.

Related Links:
University of Michigan Medical School


New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.